Recommended Topic Related To:

Vira-A

"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle “ every drug that FDA approves “ carries some risk. One of the first lines of defense against "...

Vira-A

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Vira-A

CLINICAL PHARMACOLOGY

VIRA-A (vidarabine) is rapidly deaminated to arabinosylhypoxanthine (Ara-Hx), the principal metabolite. Ara-Hx also possesses in vitro antiviral activity but this activity is less than that of VIRA-A (vidarabine) . Because of the low solubility of VIRA-A (vidarabine) , trace amounts of both VIRA-A (vidarabine) and Ara-Hx can be detected in the aqueous humor only if there is an epithelial defect in the cornea. If the cornea is normal, only trace amounts of Ara-Hx can be recovered from the aqueous humor.

Systemic absorption of VIRA-A (vidarabine) should not be expected to occur following ocular administration and swallowing lacrimal secretions. In laboratory animals, VIRA-A (vidarabine) is rapidly deaminated in the gastrointestinal tract to Ara-Hx.

In contrast to topical idoxuridine, VIRA-A (vidarabine) demonstrated less cellular toxicity in the regenerating corneal epithelium of the rabbit.

In controlled and uncontrolled clinical trials, an average of seven and nine days of continuous VIRA-A (vidarabine) Ophthalmic Ointment, 3%, therapy was required to achieve corneal re-epithelialization. In the controlled trials, 70 of 81 subjects (86%) re-epithelialized at the end of three weeks of therapy. In the uncontrolled trials, 101 of 142 subjects (71%) re-epithelialized at the end of three weeks.

Seventy-five percent of the subjects in these uncontrolled trials had either not healed previously or had developed hypersensitivity to topical idoxuridine therapy.

Microbiology

Vidarabine is a purine nucleoside obtained from fermentation cultures of Streptomyces antibioticus. The antiviral mechanism of action has not been established. Vidarabine appears to interfere with the early steps of viral DNA synthesis.

Vidarabine has been shown to possess antiviral activity against the following viruses in vitro:

Herpes simplex types 1 and 2
Vaccinia
Varicella-Zoster

Except for Rhabdovirus and Oncornavirus, vidarabine does not display in vitro antiviral activity against other RNA or DNA viruses, including Adenovirus.

Susceptibility Tests

No universal, standardized, quantitative in vitro procedures have as yet been developed to estimate the susceptibility of viruses to antiviral agents.

Last reviewed on RxList: 4/8/2009
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations